CD-10: An Emerging biomarker in Prognostication of Infiltrating Duct Carcinoma Breast
Keywords:
Carcinoma breast, CD10, Estrogen Receptor, Progesterone Receptor, Her2neu
Abstract
BACKGROUND: All carcinomas of the breast can be classified based on the hormone receptors on cells and also by cell of origin. Generally most of health setup in developing countries carries out assessment of tumour behavior for breast cancer based on three parameters: tumour size, lymph node status, and histological grade. A few better established medical institutes have added immunohistochemistry to forecast the tumour outcome and guide the clinicians for better management of such patients. In carcinoma breast prognostic panel consisting of Estrogen Receptor (ER), Progesterone Receptor (PR) & Her2neu is being commonly used for prognostication of the Infiltrating duct carcinomas (IDC). With new breakthrough in the field it has become clear that stroma also plays a significant role in the spread of carcinoma breast and the proliferation rate of tumors has been shown to be a good predictor of aggressiveness of the tumor, hence new markers such as Ki67gene over expression and CD 10 have been added to the armament for prognostication . The aims of this study are to estimate the frequency of expression of stromal CD10 in invasive breast carcinomas and also to assess prognostic significance of stromal CD10 marker.METHODS: In this study, we examined 20 cases of invasive breast carcinoma. Apart from routine H&E stain, the selected cases were stained with concurrent immunohistochemical prognostic panel (ER, PR, Her2neu) and CD10 stromal marker, to characterize and to identify prognostic markers that can identify tumors with more aggressive behavior. RESULT: We found 06 cases were of the triple-negative phenotype (ER, PR, Her2neu) and all exhibited strong CD10 stromal positivity. The majority of these tumors were grade III, IDC. There were positive associations with larger size, pushing margins, poorer Nottingham Prognostic Index (NPI). In all tumors, we considered tumor size, lymph node stage, and hormone receptors as the most useful prognostic markers and found that the traditional markers indicating poor outcome correlated well with CD 10 stromal positivity in 80% cases. CONCLUSION: In the present study all triple-negative cases with positive nodal status , larger tumor size and higher grade, the hormonal expression revealed a strong correlation with CD 10 marker which appears to be a very strong potential and the most useful emerging prognostic marker.References
1. Two-year report of the population based cancer registries, 1999-2000, National cancer registry programme. (Last accessed on 2013 Nov 15) in ICMR Report [Internet]
2. Mori I, Yang Q, Kakudo K. Predictive and prognostic markers for invasive breast cancer. Pathol Int. 2002; 52: 186–194.
3. Makretsov NA, Hayes M, Carter BA, et al. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol 2007; 20(1): 84-9.
4. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat.1992; 22: 207–219.
5. Iwaya K, Ogawa H, Izumi M, Kuroda M, Mukai K. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virchows Arch 2002; 440(6): 589-93.
6. Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Modern Pathology, 2007.1, 84–89,
7. Masaki T, Keiichi I, Masahiko K, Miki I. The stromal expression of CD10 in breast carcinoma. J of Tokyo Med University 2001; 59: 45-50.
8.Yazho C, Wenlv S, Weidong Z, Licun W. Clinicopathological significance of stromal myofibroblast in invasive ductal carcinoma of breast. Tumor boil 2004;25:290-5.
9. Martinez, C. Bianco, M. De Santis, et al., EGFR related peptides and their cognate receptors in breast cancer in Breast Cancer; In: Molecular Genetics Pathogenesis and Therapeutics, Humana Press, Totowa, NJ, USA, 2nd edition, 2001, 31–57.
2. Mori I, Yang Q, Kakudo K. Predictive and prognostic markers for invasive breast cancer. Pathol Int. 2002; 52: 186–194.
3. Makretsov NA, Hayes M, Carter BA, et al. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Mod Pathol 2007; 20(1): 84-9.
4. Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat.1992; 22: 207–219.
5. Iwaya K, Ogawa H, Izumi M, Kuroda M, Mukai K. Stromal expression of CD10 in invasive breast carcinoma: a new predictor of clinical outcome. Virchows Arch 2002; 440(6): 589-93.
6. Makretsov NA, Hayes M, Carter BA, Dabiri S, Gilks CB, Huntsman DG. Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. Modern Pathology, 2007.1, 84–89,
7. Masaki T, Keiichi I, Masahiko K, Miki I. The stromal expression of CD10 in breast carcinoma. J of Tokyo Med University 2001; 59: 45-50.
8.Yazho C, Wenlv S, Weidong Z, Licun W. Clinicopathological significance of stromal myofibroblast in invasive ductal carcinoma of breast. Tumor boil 2004;25:290-5.
9. Martinez, C. Bianco, M. De Santis, et al., EGFR related peptides and their cognate receptors in breast cancer in Breast Cancer; In: Molecular Genetics Pathogenesis and Therapeutics, Humana Press, Totowa, NJ, USA, 2nd edition, 2001, 31–57.
Published
2016-08-12
Issue
Section
Original Article
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
